Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Hepatic

News

Alkermes Regains Full Commercialization Rights to VIVITROL® in US

Published December 1, 2008, 5:00 am, Business Wire via Yahoo! Finance

CAMBRIDGE, Mass.----Alkermes, Inc. today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL® in the U.S. following a portfolio review by Cephalon.

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Hepatic Stories

From Various News Sources

Cephalon ending partnership in alcohol drug - Daily Local News
Cephalon Inc. of East Whiteland announced Monday it is ending its collaboration to co-promote an injectable drug used to treat alcohol dependence. Its partner in the collaboration, Alkermes Inc. of Cambridge, Mass., said it has regained full ...

Alkermes Regains Full Commercialization Rights to VIVITROL in US - Phramalive.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 1, 2008 - Alkermes, Inc. (NASDAQ: ALKS) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL ® (naltrexone for extended-release injectable suspension) in the U.S ...

Alkermes Regains Full Commercialization Rights to VIVITROL® in US - Genetic Engineering News
Alkermes, Inc. ( NASDAQ: ALKS ) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL ® (naltrexone for extended-release injectable suspension) in the U.S. following a portfolio review by Cephalon. The ...

Alkermes regains US rights to alcohol drug - Boston Globe
Alkermes Inc ., a Cambridge biotechnolgy company, said today that it has regained from Cephalon Inc. full commercialization rights to Vivitrol, once-monthly, extended-release injectable medication for the treatment of alcohol dependence. The ...

Alkermes (ALKS) Regains Full Commercial Rights to VIVITROL(R) in US ... - StreetInsider.com
Alkermes, Inc. (NASDAQ: ALKS ) today announced that it has regained from Cephalon, Inc. (Nasdaq: CEPH ) full commercialization rights to VIVITROL(R) in the U.S. following a portfolio review by Cephalon. The collaboration between the two companies ...

Related Social Bookmarks

None found at this time.